Literature DB >> 21704110

Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection.

Chelsea D Voytek1, Kevin T Jones, David S Metzger.   

Abstract

Efficacy studies of investigational HIV vaccines require enrollment of individuals at 'high risk' for HIV. This paper examines participation in HIV vaccine trials among women at 'high risk' for HIV acquisition. In-depth interviews were conducted with 17 African-American women who use crack cocaine and/or exchange sex for money/drugs to elicit attitudes toward medical research and motivators and deterrents to HIV vaccine trial participation. Interviews were digitally recorded and transcribed; data were coded and compiled into themes. Most women expressed favorable attitudes toward medical research in general. Motivators for trial participation included compensation; personal benefits including information, social services, and the possibility that the trial vaccine could prevent HIV; and altruism. Deterrents included: dislike of needles; distrust; concern about future consequences of participating. In addition, contingencies, care-giving responsibilities, and convenience issues constituted barriers which could impede participation. Respondents described varied, complex perspectives, and individual cases illustrate how these themes played out as women contemplated trial participation. Understanding factors which influence vaccine research participation among women at 'high risk' can aid sites to tailor recruitment procedures to local contexts. Concerns about future reactions can be addressed through sustained community education. Convenience barriers can be ameliorated by providing rides to study visits when necessary, and/or conducting study visits in accessible neighborhood locations. Women in this sample thought carefully about enrolling in HIV vaccine trials given the structural constraints within which they lived. Further research is needed regarding structural factors which influence personal agency and individuals' thinking about research participation.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704110      PMCID: PMC3164286          DOI: 10.1016/j.vaccine.2011.06.064

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  29 in total

Review 1.  African American participation in clinical trials: recruitment difficulties and potential remedies.

Authors:  Ashish Chandra; David P Paul
Journal:  Hosp Top       Date:  2003

2.  "Once Bitten, Twice Shy": participant perspectives in the aftermath of an early HIV vaccine trial termination.

Authors:  P A Newman; S Yim; A Daley; R Walisser; R Halpenny; W Cunningham; M Loutfy
Journal:  Vaccine       Date:  2010-11-12       Impact factor: 3.641

Review 3.  Under the shadow of Tuskegee: African Americans and health care.

Authors:  V N Gamble
Journal:  Am J Public Health       Date:  1997-11       Impact factor: 9.308

4.  Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note.

Authors:  M A Chesney; D B Chambers; J O Kahn
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-12-01

5.  African Americans' views on research and the Tuskegee Syphilis Study.

Authors:  V S Freimuth; S C Quinn; S B Thomas; G Cole; E Zook; T Duncan
Journal:  Soc Sci Med       Date:  2001-03       Impact factor: 4.634

6.  Factors affecting African-American participation in AIDS research.

Authors:  S Sengupta; R P Strauss; R DeVellis; S C Quinn; B DeVellis; W B Ware
Journal:  J Acquir Immune Defic Syndr       Date:  2000-07-01       Impact factor: 3.731

7.  Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities.

Authors:  R P Strauss; S Sengupta; S Kegeles; E McLellan; D Metzger; S Eyre; F Khanani; C B Emrick; K M MacQueen
Journal:  J Acquir Immune Defic Syndr       Date:  2001-01-01       Impact factor: 3.731

8.  Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study.

Authors:  G R Seage; S E Holte; D Metzger; B A Koblin; M Gross; C Celum; M Marmor; G Woody; K H Mayer; C Stevens; F N Judson; D McKirnan; A Sheon; S Self; S P Buchbinder
Journal:  Am J Epidemiol       Date:  2001-04-01       Impact factor: 4.897

9.  Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States.

Authors:  B A Koblin; P Heagerty; A Sheon; S Buchbinder; C Celum; J M Douglas; M Gross; M Marmor; K Mayer; D Metzger; G Seage
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

10.  Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation.

Authors:  Susan P Buchbinder; Barbara Metch; Sarah E Holte; Susan Scheer; Anne Coletti; Eric Vittinghoff
Journal:  J Acquir Immune Defic Syndr       Date:  2004-05-01       Impact factor: 3.731

View more
  15 in total

1.  Curriculum development to increase minority research literacy for HIV prevention research: a CBPR approach.

Authors:  Malika Roman Isler; Andre L Brown; Natalie Eley; Allison Mathews; Kendra Batten; Randy Rogers; Noah Powell; Caressa White; Rosalee Underwood; Kathleen M MacQueen
Journal:  Prog Community Health Partnersh       Date:  2014

Review 2.  A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders.

Authors:  Sheba George; Nelida Duran; Keith Norris
Journal:  Am J Public Health       Date:  2013-12-12       Impact factor: 9.308

3.  Sources of racial/ethnic differences in awareness of HIV vaccine trials.

Authors:  Michael P Arnold; Michele Andrasik; Stewart Landers; Shelly Karuna; Matthew J Mimiaga; Steven Wakefield; Kenneth Mayer; Susan Buchbinder; Beryl A Koblin
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

4.  Food Insecurity, Financial Hardship, and Mental Health Among Multiple Asian American Ethnic Groups: Findings from the 2020 COVID-19 Household Impact Survey.

Authors:  Jessica Y Islam; Iman Awan; Farzana Kapadia
Journal:  Health Equity       Date:  2022-06-24

5.  The Motivations and Experiences of Young Women in a Microbicide Trial in the USA and Puerto Rico.

Authors:  Rebecca Giguere; Gregory D Zimet; Jessica A Kahn; Curtis Dolezal; Cheng-Shiun Leu; Marina Mabragaña; Ian McGowan; Alex Carballo-Diéguez
Journal:  World J AIDS       Date:  2013-09

6.  Bridging the divide: HIV prevention research and Black men who have sex with men.

Authors:  Michele Peake Andrasik; Christian Chandler; Borris Powell; Damon Humes; Steven Wakefield; Katharine Kripke; Daniel Eckstein
Journal:  Am J Public Health       Date:  2014-02-13       Impact factor: 9.308

7.  Recruitment of urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials.

Authors:  Barbara Metch; Ian Frank; Richard Novak; Edith Swann; David Metzger; Cecilia Morgan; Debbie Lucy; Debora Dunbar; Parrie Graham; Tamra Madenwald; Gina Escamilia; Beryl Koblin
Journal:  AIDS Behav       Date:  2013-02

8.  Exploring barriers and facilitators to participation of male-to-female transgender persons in preventive HIV vaccine clinical trials.

Authors:  Michele Peake Andrasik; Ro Yoon; Jessica Mooney; Gail Broder; Marcus Bolton; Teress Votto; Annet Davis-Vogel
Journal:  Prev Sci       Date:  2014-06

9.  Representation of Latinos and Blacks in screening for and enrollment into preventive HIV vaccine trials in New York City.

Authors:  Tanya M Ellman; Kellie Hawkins; Jorge Benitez; Ramon Negron; Steven Chang; Steven Palmer; Verna Robertson; Mary Ann Chiasson; Magdalena E Sobieszczyk
Journal:  Vaccine       Date:  2015-10-11       Impact factor: 3.641

Review 10.  Improving African American women's engagement in clinical research: A systematic review of barriers to participation in clinical trials.

Authors:  Daisy Le; Hanna Ozbeki; Stefanie Salazar; Madison Berl; Monique Mitchell Turner; Olga Acosta Price
Journal:  J Natl Med Assoc       Date:  2022-03-10       Impact factor: 2.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.